Jazz Pharmaceuticals JAZZ Cash, Cash Equivalents, and Short-Term Investments, Amortized Cost
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept jazz:CashCashEquivalentsAndShortTermInvestmentsAmortizedCost.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's cash, cash equivalents, and short-term investments, amortized cost.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's cash, cash equivalents, and short-term investments, amortized cost?
- Jazz Pharmaceuticals (JAZZ) reported cash, cash equivalents, and short-term investments, amortized cost of $2.87B in Q1 2026.